MedTrace Logo

Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas

NCT03916003 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2023-11-21

No results posted yet for this study

Summary

This study is designed as a multi-centre randomized, open label trial to compare the safety and efficacy of a high dose primaquine (PQ) treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice of providing only schizontocidal treatment.

Conditions

  • Malaria
  • Vivax Malaria
  • Falciparum Malaria

Interventions

DRUG

primaquine

Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)

Sponsors & Collaborators

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • Tribhuvan University, Nepal

    collaborator OTHER

  • Arba Minch University

    collaborator OTHER

  • Addis Ababa University

    collaborator OTHER

  • Menzies School of Health Research

    lead OTHER

Principal Investigators

  • Kamala Thriemer, MD · Menzies School of Health Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-18
Primary Completion
2022-05-14
Completion
2022-07-30

Countries

  • Bangladesh
  • Ethiopia
  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03916003 on ClinicalTrials.gov